Pfizer (PFE)

Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts. Chief Executive Officer Albert Bourla said the company’s launched and

Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...

Pfizer lifts guidance as newer drugs grow, even as COVID sales keep falling.

BioNTech (NASDAQ:BNTX) reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology

Pfizer's revenue didn't grow, but the mix underneath it changed a lot.

The healthcare stock may finally have the catalyst that it needs to take off before the end of the year.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1...

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Panama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Pfizer's post-COVID comeback is still only in the early stages.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

The stocks listed here yield up to 5.8%.

These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.

Pfizer has a plan to bounce back from recent obstacles.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

One of these pharma stocks offers more income, but the other offers a safer dividend.